Abstract
BACKGROUND: Medication side effects and limited efficacy are substantial problems in general and also in psychopharmaceuticals. Previous studies have shown that pharmacogenetic individual characteristics can be relevant. AIM: To arrive at a responsible use of pharmacogenetics, exploiting its potential but also avoiding overdiagnosis. METHOD: To provide an overview of the current status quo in the field of pharmacogenetics in psychiatry. RESULTS: The Dutch Association for Psychiatrists (NVvP) authorized a guideline ‘Pharmacogenetics in Psychiatry’ that is summarized. Also the current international guidelines and clinical implementation of pharmacogenetics are discussed. CONCLUSION: For the time being, pharmacogenetics seems to be indicated only when patients have already experienced problems with psychopharmaca use, such as side effects and/or inefficacy. If genotyping is requested then generally CYP2C19 and CYP2D6 can be useful, as dosage recommendations are available in case of genetic variants.
| Translated title of the contribution | Current status quo on Pharmacogenetics in psychiatry |
|---|---|
| Original language | Dutch |
| Pages (from-to) | 312-316 |
| Number of pages | 5 |
| Journal | Tijdschrift voor Psychiatrie |
| Volume | 64 |
| Issue number | 5 |
| Publication status | Published - 10 May 2022 |
Keywords
- Cytochrome P-450 CYP2D6/genetics
- Humans
- Pharmacogenetics
- Psychiatry
- Psychotropic Drugs